tiprankstipranks
Indaptus Therapeutics reports 2022 EPS ($1.73) vs ($1.89) last year
The Fly

Indaptus Therapeutics reports 2022 EPS ($1.73) vs ($1.89) last year

As of December 31, 2022, the Company had cash and cash equivalents and marketable securities of approximately $26.4 million. "With the initiation of our INDP-D101 trial at the end of December 2022 and the subsequent dosing of our first patient in the first cohort, we are well underway in our Phase 1 trial of Decoy20 for the treatment of solid tumors," said Jeffrey Meckler, chief executive officer of Indaptus. "Following the initial dosing we were encouraged to learn that the subject experienced manageable and expected adverse events related to the immune response we anticipated. We are looking forward to analyzing the data generated from that first patient and finishing the first arm of the trial per the protocol. As we continue to bring new centers online and enroll patients, we will continue to prudently manage our cash position, and update stakeholders on our progress as it develops."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on INDP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles